Cortechs.ai | Predicting progression of MCI

Predicting progression of MCI

Predicting Progression of Mild Cognitive Impairment to Alzheimer’s Disease: Hippocampal Occupancy Score (HOC)

The NeuroQuant Dementia report includes a Hippocampal Occupancy (HOC) Score and volumes of the hippocampi, superior and inferior lateral ventricles, and the entorhinal cortex, which are important biomarkers used in predicting progression of Mild Cognitive Impairment (MCI) to Alzheimer’s disease (AD). As with all NeuroQuant reports, the brain structure volumes and the HOC are compared to healthy patients of the same age and sex, normalized for intracranial volume (ICV).

Current research has demonstrated the effectiveness of the HOC in assessing patient progression from mild cognitive impairment (MCI) to Alzheimer’s disease (AD). This proven biomarker is an invaluable factor in predicting the progression of neurodegenerative diseases as approximately 10 – 15% of all patients diagnosed with MCI will develop AD annually [1]. Hippocampal volume remains the best single predictor of conversion of MCI to AD at a 3-year follow-up [2].

The HOC measures the degree of hippocampal atrophy accounting for volume loss and compensatory inferior lateral ventricle (ILV) expansion. It is calculated as a ratio of hippocampal volume to the sum of the hippocampal and ILV volumes in each hemisphere separately, which are then averaged and normalized for age and sex. The equation is as follows:

Cortechs.ai | Predicting progression of MCI

 

The NeuroQuant Dementia report provides the HOC in the first row of the table below the segmented images. The HOC is then visualized on the graph below the table to the far left, where it is plotted against the age and sex normalized values. The normative range (5th – 95th percentile) is represented in the white area of the graph while the solid line represents the mean. 

Below are a few examples to better illustrate how the HOC is interpreted with the rest of the information provided on the NeuroQuant Dementia report.

Example Cases

Case 1: 

Cortechs.ai | Predicting progression of MCI

  • Two T1 MRI scans of a 67-year-old male patient.
  • HOC measures .69 cm3 which is within two standard deviations of the normative range for age and sex.
  • The hippocampi, lateral ventricles, and inferior lateral ventricles are all within two standard deviations of the normative range for age and sex.
  • Conclusion: Normal follow-up that does not support neurodegeneration or the progression from MCI to AD. 

Case 2:

Cortechs.ai | Predicting progression of MCI 

  • A single T1 MRI scan of a 36-year-old female.
  • HOC measures 0.66 cm3. The mesial temporal lobe is more than two standard deviations from the normative range for age and sex. 
  • The hippocampi demonstrate atrophy and are beyond two deviations below the normative range for age and sex.
  • The lateral ventricles and inferior lateral ventricles are enlarged beyond two standard deviations of the normative range for age and sex.

Conclusion: Low hippocampal volume and suggestive of local ex-vacuo dilatation. This supports mesial temporal lobe-focused neurodegenerative etiology. Suggestive of the progression from MCI to AD.

This measure not only aids in the differentiation of individuals with congenitally small hippocampi from those with small hippocampi due to a degenerative disorder but also effectively demonstrates the risk of conversion from MCI to AD. 

Citations:

[1] Biomarkers for the clinical evaluation of the cognitively impaired elderly: amyloid is not enough

[2] Predictive Utility of Marketed Volumetric Software Tools in Subjects at Risk for Alzheimer Disease: Do Regions Outside the Hippo

More Resources

11/17/2025

Unlocking the Value of NeuroQuant Reports: Different Use Cases Across Clinical Practice

From neurodegeneration and demyelination to development, trauma, and seizures, NeuroQuant supports better decision‑making, communication, and patient care

11/17/2025

Case Study: Augmenting Prostate Imaging Programs with OnQ™ Prostate

Discover how Imaging Healthcare Specialists integrated OnQ™ Prostate to enhance lesion visibility, boost diagnostic confidence, and improve communication.

11/04/2025

NeuroQuant Dementia in Different Use Cases 

NeuroQuant transforms brain imaging into a measurable biomarker for neurodegeneration by combining volumetric data with clinical expertise.

10/29/2025

Enhancing Brain Tumor Treatment with RT STRUCT Images: The Promise of Automation

Automating the generation of RT STRUCT images with NeuroQuant Brain Tumor can streamline workflows and elevate the standard of care

10/15/2025

Sharper Screening, Smarter Biopsies: OnQ Prostate and the Next Step in Imaging

Read to learn how OnQ Prostate goes beyond existing solutions like DynaCAD and redefines biopsy precision

10/14/2025

Cortechs.ai Acquires ZepMed to Expand AI-Powered Neuroimaging Capabilities

This strategic acquisition strengthens Cortechs.ai’s position at the forefront of radiological innovation and expands its suite of best-in-class solutions
Scroll to Top